Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial.
Roche delivered a double-digit sales increase in the first quarter, but CEO Severin Schwan still thinks the company’s full-year haul may come in flat versus 2021.
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore
After last year’s surprise flop in previously untreated hepatocellular carcinoma (HCC) the most common type of liver cancer Exelixis’ hopes dimmed around the combination of its tyrosine kinase inhi
After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free